GM3 synthase deficiency

Mendelian MONDO:0018274 Pathograph 27 Congenital disorder of glycosylation Glycosphingolipid biosynthesis disorder

GM3 synthase deficiency is an autosomal recessive congenital disorder of glycosylation caused by biallelic pathogenic variants in ST3GAL5. ST3GAL5 encodes GM3 synthase, the sialyltransferase that converts lactosylceramide to ganglioside GM3, an upstream precursor for nearly all complex gangliosides in neural tissue. Loss of GM3 synthase activity depletes GM3 and downstream gangliosides, remodels glycosphingolipid and cell-surface signaling programs, and causes severe infantile-onset neurodevelopmental disease with irritability, feeding difficulty, failure to thrive, refractory seizures, developmental delay or regression, profound intellectual disability, visual and hearing impairment, movement disorder, hypotonia, and abnormal skin pigmentation.

Ask OpenScientist

Ask a research question about GM3 synthase deficiency. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Definitions
1
Inheritance
4
Pathophys.
17
Phenotypes
27
Pathograph
1
Genes
2
Treatments
11
References
1
Deep Research
🔗

Mappings

MONDO
MONDO:0018274 GM3 synthase deficiency
skos:exactMatch Orphanet ORPHA:370933
Orphanet ORPHA:370933 lists MONDO:0018274 as an exact cross-reference for GM3 synthase deficiency.
📘

Definitions

1
Orphanet GM3 synthase deficiency definition
A rare congenital disorder of glycosylation due to impaired synthesis of complex gangliosides, initially characterized by irritability, poor feeding, failure to thrive, and early-onset refractory epilepsy, followed by growth impairment, severe developmental delay or regression, profound intellectual disability, deafness, abnormal skin pigmentation, visual impairment, choreoathetosis, hypotonic tetraparesis, and sometimes dysmorphic facial features.
OTHER
Show evidence (1 reference)
ORPHA:370933 SUPPORT Other
"due to impaired synthesis of complex ganglioside species"
Orphanet defines the disorder by impaired complex ganglioside synthesis.
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
GM3 synthase deficiency is inherited in an autosomal recessive pattern.
Autosomal recessive inheritance
Show evidence (2 references)
ORPHA:370933 SUPPORT Other
"Autosomal recessive"
Orphanet records autosomal recessive inheritance for GM3 synthase deficiency.
PMID:15502825 SUPPORT Human Clinical
"autosomal recessive infantile-onset symptomatic epilepsy"
The original clinical report describes autosomal recessive disease in affected families.
⚙

Pathophysiology

4
ST3GAL5 GM3 synthase loss of function
Pathogenic ST3GAL5 variants reduce or abolish GM3 synthase activity, blocking the sialylation step that produces ganglioside GM3 from lactosylceramide.
ST3GAL5 link
glycosphingolipid biosynthetic process link ↓ DECREASED
lactosylceramide alpha-2,3-sialyltransferase activity link ↓ DECREASED
Downstream
Reduced GM3 synthase activity Pathogenic ST3GAL5 variants abolish or markedly reduce GM3 synthase enzyme activity.
GM3 and downstream ganglioside depletion Loss of GM3 synthase activity depletes GM3 and biosynthetic derivatives.
Show evidence (2 references)
PMID:15502825 SUPPORT Human Clinical
"premature termination of the GM3 synthase enzyme"
The original report identifies a truncating ST3GAL5 variant affecting GM3 synthase.
PMID:30576498 SUPPORT In Vitro
"revealed a complete loss of enzyme activity."
Transfected-cell enzyme assays show complete loss of GM3 synthase activity for pathogenic variants.
GM3 and downstream ganglioside depletion
Because GM3 is the precursor for most complex gangliosides, GM3 synthase loss causes absence of GM3 and downstream a-, b-, and c-series gangliosides with accumulation of upstream lactosylceramide-related species.
ST3GAL5 link
ganglioside metabolic process link ⚠ ABNORMAL
Downstream
GM3 ganglioside depletion Loss of GM3 synthase causes absent or markedly reduced GM3 ganglioside in affected individuals.
Complex ganglioside depletion Because GM3 is upstream of most complex gangliosides, downstream ganglioside species are depleted.
Glycosphingolipid remodeling Ganglioside depletion shifts glycosphingolipid composition and glycosylation programs.
Neural cell signaling vulnerability Complex ganglioside loss alters cell-surface signaling in neural lineage cells.
Show evidence (3 references)
PMID:15502825 SUPPORT Human Clinical
"affected individuals lack GM3 synthase"
Plasma glycosphingolipid analysis supports absent GM3 synthase activity in affected individuals.
PMID:30209782 SUPPORT Human Clinical
"causes an absence of GM3 and all"
The clinical supplementation study summarizes the core biochemical absence of GM3 derivatives.
PMID:37676252 SUPPORT In Vitro
"GM3-derived gangliosides were undetectable"
Patient-derived iPSC and neural crest models confirm undetectable GM3-derived gangliosides.
Glycosphingolipid remodeling
Loss of the GM3 branch alters glycosphingolipid composition and collateral glycan programs in patient cells and model systems.
glycosphingolipid biosynthetic process link ⚠ ABNORMAL
Downstream
Altered glycosphingolipid profile Loss of GM3-derived gangliosides produces a measurable abnormal glycosphingolipid profile in patient-derived cells.
Neural cell signaling vulnerability Altered glycosphingolipid profiles perturb membrane and receptor signaling states.
Abnormality of skin pigmentation Glycolipid and glycoprotein glycosylation remodeling is associated with the neurocutaneous pigmentation phenotype.
Abnormal facial shape Dysmorphic facial features are reported in ST3GAL5-related neurocutaneous disease, but the cached evidence does not resolve the intermediate morphogenetic mechanism.
Show evidence (2 references)
PMID:24026681 SUPPORT In Vitro
"revealed collateral alterations in response"
Patient fibroblast glycomic analysis supports broader glycosylation remodeling.
PMID:37676252 SUPPORT In Vitro
"Altered GSL profiles in GM3SD cells"
Patient-derived neural lineage cells show altered GSL profiles and downstream cellular changes.
Neural cell signaling vulnerability
Complex ganglioside depletion in patient-derived neural lineage cells alters receptor tyrosine kinase abundance, O-GlcNAcylation, and apoptosis susceptibility, providing a plausible cellular route from glycosphingolipid biosynthesis failure to neurodevelopmental dysfunction.
neural cell link migratory neural crest cell link
cell surface receptor protein tyrosine kinase signaling pathway link ⚠ ABNORMAL apoptotic process link ↑ INCREASED
Downstream
Seizure Neural membrane and signaling disruption contributes to severe infantile epilepsy.
Global developmental delay Neural-lineage signaling and survival defects contribute to severe developmental impairment.
Visual impairment Neural tissue vulnerability contributes to cortical visual impairment and optic pathway disease.
Hearing impairment Ganglioside biology in neural tissues is linked to the sensorineural phenotype.
Irritability Severe neural dysfunction in infancy is associated with prominent irritability.
Feeding difficulties Early neurologic disease is associated with poor feeding in infancy.
Failure to thrive Infantile neurologic disease and poor feeding are associated with failure to thrive.
Growth delay Feeding difficulty, failure to thrive, and severe neurodevelopmental disease are associated with postnatal growth impairment.
Developmental regression Neural-lineage signaling and survival defects are associated with developmental regression in the progressive disease course.
Intellectual disability Severe neural dysfunction is associated with profound intellectual disability.
Optic atrophy Neural and optic pathway vulnerability is associated with optic atrophy or pale papillae.
Choreoathetosis Neural signaling vulnerability is associated with hyperkinetic movement disorder including choreoathetosis.
Hypotonia Neural motor system involvement is associated with hypotonic tetraparesis.
Scoliosis Scoliosis is reported in ST3GAL5-related salt-and-pepper syndrome, but the cached evidence does not resolve the intermediate skeletal or neuromotor mechanism.
Microcephaly Severe neurodevelopmental disease is associated with progressive microcephaly.
Show evidence (3 references)
PMID:37676252 SUPPORT In Vitro
"exhibited increased apoptosis"
Patient-derived neural crest cells show increased apoptosis and altered signaling.
PMID:24026681 SUPPORT Model Organism
"Morphant zebrafish embryos also exhibited increased apoptotic cell death"
Zebrafish knockdown supports increased brain-region apoptosis after st3gal5 loss.
PMID:18480157 SUPPORT In Vitro
"dampens membrane EGFR activation"
Patient fibroblasts show altered EGFR signaling after ganglioside depletion.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for GM3 synthase deficiency Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

17
Digestive 1
Feeding difficulties FREQUENT Feeding difficulties (HP:0011968)
Show evidence (1 reference)
ORPHA:370933 SUPPORT Other
"poor feeding, failure to thrive"
Orphanet lists poor feeding among initial features.
Ear 1
Hearing impairment FREQUENT Hearing impairment (HP:0000365)
Show evidence (2 references)
ORPHA:370933 SUPPORT Other
"profound intellectual disability, deafness"
Orphanet lists deafness as a feature.
PMID:34906476 SUPPORT Human Clinical
"optic atrophy or pale papillae, and hearing loss"
The non-Amish cohort identifies hearing loss among main features.
Eye 2
Visual impairment FREQUENT Visual impairment (HP:0000505)
Show evidence (2 references)
ORPHA:370933 SUPPORT Other
"Visual impairment due to cortical atrophy"
Orphanet lists visual impairment due to cortical atrophy.
PMID:30576498 SUPPORT Human Clinical
"severe hearing, visual, motor, and cognitive impairment"
A reported ST3GAL5-CDG patient had severe visual impairment.
Optic atrophy FREQUENT Optic atrophy (HP:0000648)
Show evidence (1 reference)
PMID:34906476 SUPPORT Human Clinical
"optic atrophy or pale papillae, and hearing loss"
The non-Amish cohort lists optic atrophy or pale papillae among main features.
Head and Neck 2
Abnormal facial shape OCCASIONAL Abnormal facial shape (HP:0001999)
Show evidence (1 reference)
ORPHA:370933 SUPPORT Other
"Dysmorphic facial features may be associated."
Orphanet notes that dysmorphic facial features may be associated.
Microcephaly FREQUENT Microcephaly (HP:0000252)
Show evidence (2 references)
PMID:34906476 SUPPORT Human Clinical
"microcephaly"
The non-Amish cohort supports microcephaly as a frequent feature.
PMID:35628171 SUPPORT Other
"progressive microcephaly, intellectual"
The review summarizes progressive microcephaly among human patient features.
Integument 1
Abnormality of skin pigmentation FREQUENT Abnormality of skin pigmentation (HP:0001000)
Show evidence (2 references)
ORPHA:370933 SUPPORT Other
"abnormalities of skin pigmentation"
Orphanet lists abnormal skin pigmentation.
PMID:34906476 SUPPORT Human Clinical
"progressive skin pigmentation anomalies"
The non-Amish cohort reports progressive skin pigmentation anomalies.
Musculoskeletal 2
Hypotonia FREQUENT Hypotonia (HP:0001252)
Show evidence (1 reference)
ORPHA:370933 SUPPORT Other
"hypotonic tetraparesis"
Orphanet's hypotonic tetraparesis description supports hypotonia.
Scoliosis OCCASIONAL Scoliosis (HP:0002650)
Show evidence (2 references)
PMID:24026681 SUPPORT Human Clinical
"severe intellectual disability, epilepsy, scoliosis, choreoathetosis, dysmorphic facial features and altered dermal pigmentation"
The human salt-and-pepper syndrome report includes scoliosis.
PMID:36833282 SUPPORT Human Clinical
"choreoathetosis, scoliosis, and dermal pigmentation along with dysmorphic facial"
The Saudi family report summarizes scoliosis among SPDRS clinical features.
Nervous System 6
Irritability FREQUENT Irritability (HP:0000737)
Show evidence (2 references)
ORPHA:370933 SUPPORT Other
"initially characterized by irritability"
Orphanet lists irritability among the initial features.
PMID:30209782 SUPPORT Human Clinical
"severe irritability, intractable seizures, and profound intellectual disability"
The clinical supplementation study lists severe irritability as a manifestation.
Seizure FREQUENT Seizure (HP:0001250)
Show evidence (2 references)
ORPHA:370933 SUPPORT Other
"early-onset refractory epilepsy"
Orphanet lists early-onset refractory epilepsy.
PMID:34906476 SUPPORT Human Clinical
"11 of 16 had epilepsy"
The non-Amish cohort supports epilepsy as a frequent feature.
Global developmental delay FREQUENT Global developmental delay (HP:0001263)
Show evidence (2 references)
ORPHA:370933 SUPPORT Other
"severe developmental delay or developmental regression"
Orphanet describes severe developmental delay or regression.
PMID:36833282 SUPPORT Human Clinical
"causing SPDRS with epilepsy, short stature, speech delay, and developmental delay in all three affected members"
The Saudi family report supports developmental delay in ST3GAL5-associated disease.
Developmental regression FREQUENT Developmental regression (HP:0002376)
Show evidence (1 reference)
ORPHA:370933 SUPPORT Other
"developmental delay or developmental regression"
Orphanet explicitly includes developmental regression.
Intellectual disability VERY_FREQUENT Intellectual disability (HP:0001249)
Show evidence (2 references)
ORPHA:370933 SUPPORT Other
"profound intellectual disability"
Orphanet lists profound intellectual disability.
PMID:34906476 SUPPORT Human Clinical
"severe to profound intellectual disability"
The non-Amish cohort found severe to profound intellectual disability in all reported patients.
Choreoathetosis VERY_FREQUENT Choreoathetosis (HP:0001266)
Show evidence (2 references)
ORPHA:370933 SUPPORT Other
"choreoathetosis and hypotonic tetraparesis"
Orphanet lists choreoathetosis.
PMID:34906476 SUPPORT Human Clinical
"14 of 16 had a hyperkinetic movement disorder"
14 of 16 non-Amish patients had hyperkinetic movement disorder, placing choreoathetosis in the very frequent band.
Growth 2
Failure to thrive FREQUENT Failure to thrive (HP:0001508)
Show evidence (2 references)
ORPHA:370933 SUPPORT Other
"poor feeding, failure to thrive"
Orphanet lists poor feeding and failure to thrive among initial features.
PMID:30576498 SUPPORT Human Clinical
"failure to thrive, severe hearing, visual, motor, and cognitive impairment"
A reported patient with a novel ST3GAL5 variant had failure to thrive.
Growth delay FREQUENT Growth delay (HP:0001510)
Show evidence (2 references)
ORPHA:370933 SUPPORT Other
"postnatal growth impairment"
Orphanet describes postnatal growth impairment.
PMID:30209782 SUPPORT Human Clinical
"growth and development were documented in these subjects"
Growth improvement during supplementation supports growth delay as a clinical treatment target.
🧬

Genetic Associations

1
ST3GAL5 (Causal loss-of-function variant)
Show evidence (3 references)
ORPHA:370933 SUPPORT Other
"Disease-causing germline mutation(s) (loss of function) in"
Orphanet asserts loss-of-function ST3GAL5 germline mutations as disease-causing.
PMID:34906476 SUPPORT Human Clinical
"loss-of-function variants in ST3GAL5 cause GM3 synthase"
The non-Amish cohort identifies biallelic ST3GAL5 loss of function as causal.
CGGV:assertion_e5ea65e3-6a02-4435-9ef5-100564d3497c-2022-04-05T160000.000Z SUPPORT Other
"ST3GAL5 | HGNC:10872 | GM3 synthase deficiency | MONDO:0018274 | AR | Definitive"
ClinGen classifies the ST3GAL5-GM3 synthase deficiency gene-disease relationship as definitive with autosomal recessive inheritance.
💊

Treatments

2
Oral ganglioside supplementation
Action: dietary intervention MAXO:0000088
Agent: ganglioside ↗
Oral ganglioside-enriched dairy supplementation has been reported to produce transient improvements in growth and development in affected children, but benefits waned after about 12 months and durable restoration of endogenous ganglioside synthesis remains an unmet therapeutic goal.
Mechanism Target:
RESTORES GM3 and downstream ganglioside depletion — Dietary gangliosides attempt to increase downstream ganglioside availability.
Show evidence (1 reference)
PMID:39119456 SUPPORT Model Organism
"increased ganglioside levels and neurogenesis in the hippocampus"
Mouse supplementation increased ganglioside levels and hippocampal neurogenesis.
Target Phenotypes: Growth delay ↗ Global developmental delay ↗
Show evidence (2 references)
PMID:30209782 SUPPORT Human Clinical
"received oral ganglioside supplement"
The clinical study administered oral ganglioside-enriched dairy supplementation.
PMID:30209782 SUPPORT Human Clinical
"transient and gradually phased out"
The study reports that clinical benefits appeared transient.
Genetic counseling
Action: genetic counseling MAXO:0000079
Genetic counseling is appropriate for affected families because the disorder is autosomal recessive and molecular diagnosis clarifies recurrence risk.
Show evidence (1 reference)
ORPHA:370933 SUPPORT Other
"Autosomal recessive"
Autosomal recessive inheritance supports recurrence-risk counseling.
🔬

Biochemical Markers

4
Reduced GM3 synthase activity (DECREASED)
Context: Direct enzyme assays show loss of GM3 synthase activity from pathogenic ST3GAL5 variants.
Pathograph Readouts
Readout Of ST3GAL5 GM3 synthase loss of function Negative Diagnostic
Reduced GM3 synthase activity reports the proximal ST3GAL5 enzymatic defect.
Show evidence (1 reference)
PMID:30576498 SUPPORT In Vitro
"revealed a complete loss of enzyme activity."
Transfected-cell assays directly show complete loss of GM3 synthase activity for pathogenic variants.
GM3 ganglioside depletion (ABSENT)
Context: Absent GM3 in plasma or cells is the direct chemical readout of the blocked ST3GAL5 sialyltransferase step.
Pathograph Readouts
Readout Of GM3 and downstream ganglioside depletion Negative Diagnostic
Absent GM3 ganglioside reports failure of the ST3GAL5-dependent biosynthetic step.
Show evidence (1 reference)
PMID:15502825 SUPPORT Human Clinical
"complete lack of GM3 ganglioside and its biosynthetic derivatives"
Plasma glycosphingolipid analysis directly documents absent GM3 ganglioside.
Complex ganglioside depletion (DECREASED)
Context: Downstream GM3-derived gangliosides are depleted because GM3 is the precursor for most complex gangliosides in neural tissue.
Pathograph Readouts
Readout Of GM3 and downstream ganglioside depletion Negative Diagnostic
Depletion of downstream gangliosides reports the broader biosynthetic consequence of absent GM3 synthase activity.
Show evidence (2 references)
PMID:30209782 SUPPORT Human Clinical
"GM3 synthase deficiency (GM3D) causes an absence of GM3 and all downstream biosynthetic derivatives."
This clinical study background supports absence of GM3 and downstream biosynthetic derivatives.
PMID:37676252 SUPPORT In Vitro
"GM3 and GM3-derived gangliosides were undetectable in cells carrying either variant"
Patient-derived neural lineage cells independently show undetectable GM3-derived gangliosides.
Altered glycosphingolipid profile (ABNORMAL)
Context: Patient-derived cells show broader glycosphingolipid remodeling beyond GM3 and downstream ganglioside depletion.
Pathograph Readouts
Readout Of Glycosphingolipid remodeling Positive Monitoring
Altered GSL profiles report compensatory glycosphingolipid remodeling downstream of GM3 depletion.
Show evidence (1 reference)
PMID:37676252 SUPPORT In Vitro
"Altered GSL profiles in GM3SD cells"
Patient-derived neural lineage cells show altered glycosphingolipid profiles.
{ }

Source YAML

click to show 
name: GM3 synthase deficiency
category: Mendelian
creation_date: '2026-05-04T13:48:31Z'
updated_date: '2026-05-20T04:46:10Z'
synonyms:
- ST3GAL5-CDG
- Amish infantile epilepsy syndrome
- Salt-and-pepper syndrome
- Salt and pepper developmental regression syndrome
description: >
  GM3 synthase deficiency is an autosomal recessive congenital disorder of
  glycosylation caused by biallelic pathogenic variants in ST3GAL5. ST3GAL5
  encodes GM3 synthase, the sialyltransferase that converts lactosylceramide to
  ganglioside GM3, an upstream precursor for nearly all complex gangliosides in
  neural tissue. Loss of GM3 synthase activity depletes GM3 and downstream
  gangliosides, remodels glycosphingolipid and cell-surface signaling programs,
  and causes severe infantile-onset neurodevelopmental disease with irritability,
  feeding difficulty, failure to thrive, refractory seizures, developmental
  delay or regression, profound intellectual disability, visual and hearing
  impairment, movement disorder, hypotonia, and abnormal skin pigmentation.
disease_term:
  preferred_term: GM3 synthase deficiency
  term:
    id: MONDO:0018274
    label: GM3 synthase deficiency
parents:
- Congenital disorder of glycosylation
- Glycosphingolipid biosynthesis disorder
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0018274
      label: GM3 synthase deficiency
    mapping_predicate: skos:exactMatch
    mapping_source: Orphanet ORPHA:370933
    mapping_justification: >
      Orphanet ORPHA:370933 lists MONDO:0018274 as an exact cross-reference for
      GM3 synthase deficiency.
external_assertions:
- name: Orphanet GM3 synthase deficiency record
  source: Orphanet
  assertion_type: structured_disease_record
  external_id: ORPHA:370933
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=370933
  description: >
    Orphanet's ORPHA:370933 structured record for GM3 synthase deficiency
    includes the exact MONDO cross-reference, OMIM cross-reference, definition,
    autosomal recessive inheritance, synonym ST3GAL5-CDG, and ST3GAL5
    loss-of-function gene assertion used in this entry.
  evidence:
  - reference: ORPHA:370933
    reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0018274 | Exact"
    explanation: Orphanet maps ORPHA:370933 to the MONDO identifier used by this entry.
  - reference: ORPHA:370933
    reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "OMIM:609056 | Exact"
    explanation: Orphanet lists OMIM:609056 as an exact external cross-reference.
definitions:
- name: Orphanet GM3 synthase deficiency definition
  definition_type: OTHER
  description: >
    A rare congenital disorder of glycosylation due to impaired synthesis of
    complex gangliosides, initially characterized by irritability, poor feeding,
    failure to thrive, and early-onset refractory epilepsy, followed by growth
    impairment, severe developmental delay or regression, profound intellectual
    disability, deafness, abnormal skin pigmentation, visual impairment,
    choreoathetosis, hypotonic tetraparesis, and sometimes dysmorphic facial
    features.
  evidence:
  - reference: ORPHA:370933
    reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "due to impaired synthesis of complex ganglioside species"
    explanation: Orphanet defines the disorder by impaired complex ganglioside synthesis.
inheritance:
- name: Autosomal recessive inheritance
  description: GM3 synthase deficiency is inherited in an autosomal recessive pattern.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: ORPHA:370933
    reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal recessive"
    explanation: Orphanet records autosomal recessive inheritance for GM3 synthase deficiency.
  - reference: PMID:15502825
    reference_title: Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "autosomal recessive infantile-onset symptomatic epilepsy"
    explanation: The original clinical report describes autosomal recessive disease in affected families.
progression:
- phase: Initial infantile presentation
  age_range: Infancy
  notes: >
    Affected infants typically develop irritability, poor feeding, failure to
    thrive, and early-onset refractory epilepsy during infancy.
  evidence:
  - reference: ORPHA:370933
    reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "initially characterized by irritability, poor feeding, failure to thrive"
    explanation: Orphanet describes the early infantile presentation.
  - reference: PMID:15502825
    reference_title: Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Infantile-onset symptomatic epilepsy syndrome"
    explanation: The original human report defines the disease as infantile-onset symptomatic epilepsy.
- phase: Progressive neurodevelopmental and sensory disease
  age_range: Infancy to childhood
  notes: >
    Later disease includes severe developmental delay or regression, profound
    intellectual disability, movement disorder, microcephaly, visual impairment,
    hearing impairment, and progressive pigmentation abnormalities.
  evidence:
  - reference: ORPHA:370933
    reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "followed by postnatal growth impairment, severe developmental delay or developmental regression"
    explanation: Orphanet describes later developmental and growth impairment.
  - reference: PMID:34906476
    reference_title: GM3 synthase deficiency in non-Amish patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "severe to profound intellectual disability"
    explanation: The non-Amish cohort supports severe childhood neurodevelopmental involvement.
genetic:
- name: ST3GAL5
  association: Causal loss-of-function variant
  gene_term:
    preferred_term: ST3GAL5
    term:
      id: hgnc:10872
      label: ST3GAL5
  variant_origin: GERMLINE
  notes: >
    GM3 synthase deficiency is caused by biallelic pathogenic ST3GAL5 variants
    that abolish or markedly impair GM3 synthase activity.
  evidence:
  - reference: ORPHA:370933
    reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Disease-causing germline mutation(s) (loss of function) in"
    explanation: Orphanet asserts loss-of-function ST3GAL5 germline mutations as disease-causing.
  - reference: PMID:34906476
    reference_title: GM3 synthase deficiency in non-Amish patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "loss-of-function variants in ST3GAL5 cause GM3 synthase"
    explanation: The non-Amish cohort identifies biallelic ST3GAL5 loss of function as causal.
  - reference: CGGV:assertion_e5ea65e3-6a02-4435-9ef5-100564d3497c-2022-04-05T160000.000Z
    reference_title: "ST3GAL5 / GM3 synthase deficiency (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ST3GAL5 | HGNC:10872 | GM3 synthase deficiency | MONDO:0018274 | AR | Definitive"
    explanation: ClinGen classifies the ST3GAL5-GM3 synthase deficiency gene-disease relationship as definitive with autosomal recessive inheritance.
pathophysiology:
- name: ST3GAL5 GM3 synthase loss of function
  description: >
    Pathogenic ST3GAL5 variants reduce or abolish GM3 synthase activity, blocking
    the sialylation step that produces ganglioside GM3 from lactosylceramide.
  genes:
  - preferred_term: ST3GAL5
    term:
      id: hgnc:10872
      label: ST3GAL5
  molecular_functions:
  - preferred_term: lactosylceramide alpha-2,3-sialyltransferase activity
    modifier: DECREASED
    term:
      id: GO:0047291
      label: lactosylceramide alpha-2,3-sialyltransferase activity
  biological_processes:
  - preferred_term: glycosphingolipid biosynthetic process
    modifier: DECREASED
    term:
      id: GO:0006688
      label: glycosphingolipid biosynthetic process
  evidence:
  - reference: PMID:15502825
    reference_title: Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "premature termination of the GM3 synthase enzyme"
    explanation: The original report identifies a truncating ST3GAL5 variant affecting GM3 synthase.
  - reference: PMID:30576498
    reference_title: Total loss of GM3 synthase activity by a normally processed enzyme in a novel variant and in all ST3GAL5 variants reported to cause a distinct congenital disorder of glycosylation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "revealed a complete loss of enzyme activity."
    explanation: Transfected-cell enzyme assays show complete loss of GM3 synthase activity for pathogenic variants.
  downstream:
  - target: Reduced GM3 synthase activity
    description: Pathogenic ST3GAL5 variants abolish or markedly reduce GM3 synthase enzyme activity.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30576498
      reference_title: Total loss of GM3 synthase activity by a normally processed enzyme in a novel variant and in all ST3GAL5 variants reported to cause a distinct congenital disorder of glycosylation.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "revealed a complete loss of enzyme activity."
      explanation: Transfected-cell GM3 synthase assays directly support loss of enzymatic activity for pathogenic ST3GAL5 variants.
  - target: GM3 and downstream ganglioside depletion
    description: Loss of GM3 synthase activity depletes GM3 and biosynthetic derivatives.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:15502825
      reference_title: Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "complete lack of GM3 ganglioside and its biosynthetic derivatives"
      explanation: Plasma biochemical analysis directly links loss of GM3 synthase activity to absent GM3 ganglioside derivatives.
- name: GM3 and downstream ganglioside depletion
  description: >
    Because GM3 is the precursor for most complex gangliosides, GM3 synthase loss
    causes absence of GM3 and downstream a-, b-, and c-series gangliosides with
    accumulation of upstream lactosylceramide-related species.
  genes:
  - preferred_term: ST3GAL5
    term:
      id: hgnc:10872
      label: ST3GAL5
  chemical_entities:
  - preferred_term: ganglioside GM3
    modifier: DECREASED
    term:
      id: CHEBI:84118
      label: ganglioside GM3
  - preferred_term: ganglioside
    modifier: DECREASED
    term:
      id: CHEBI:28892
      label: ganglioside
  biological_processes:
  - preferred_term: ganglioside metabolic process
    modifier: ABNORMAL
    term:
      id: GO:0001573
      label: ganglioside metabolic process
  evidence:
  - reference: PMID:15502825
    reference_title: Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "affected individuals lack GM3 synthase"
    explanation: Plasma glycosphingolipid analysis supports absent GM3 synthase activity in affected individuals.
  - reference: PMID:30209782
    reference_title: Oral Ganglioside Supplement Improves Growth and Development in Patients with Ganglioside GM3 Synthase Deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "causes an absence of GM3 and all"
    explanation: The clinical supplementation study summarizes the core biochemical absence of GM3 derivatives.
  - reference: PMID:37676252
    reference_title: Neural-specific alterations in glycosphingolipid biosynthesis and cell signaling associated with two human ganglioside GM3 synthase deficiency variants.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "GM3-derived gangliosides were undetectable"
    explanation: Patient-derived iPSC and neural crest models confirm undetectable GM3-derived gangliosides.
  downstream:
  - target: GM3 ganglioside depletion
    description: Loss of GM3 synthase causes absent or markedly reduced GM3 ganglioside in affected individuals.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:15502825
      reference_title: Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "complete lack of GM3 ganglioside and its biosynthetic derivatives"
      explanation: Plasma glycosphingolipid analysis directly supports absent GM3 ganglioside in affected individuals.
  - target: Complex ganglioside depletion
    description: Because GM3 is upstream of most complex gangliosides, downstream ganglioside species are depleted.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30209782
      reference_title: Oral Ganglioside Supplement Improves Growth and Development in Patients with Ganglioside GM3 Synthase Deficiency.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "GM3 synthase deficiency (GM3D) causes an absence of GM3 and all downstream biosynthetic derivatives."
      explanation: Clinical supplementation study background directly supports absence of downstream GM3 biosynthetic derivatives.
  - target: Glycosphingolipid remodeling
    description: Ganglioside depletion shifts glycosphingolipid composition and glycosylation programs.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24026681
      reference_title: "A mutation in a ganglioside biosynthetic enzyme, ST3GAL5, results in salt & pepper syndrome, a neurocutaneous disorder with altered glycolipid and glycoprotein glycosylation."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "revealed collateral alterations in response to loss of complex gangliosides"
      explanation: Patient fibroblast glycomic analysis supports glycosphingolipid and glycan remodeling after complex ganglioside loss.
  - target: Neural cell signaling vulnerability
    description: Complex ganglioside loss alters cell-surface signaling in neural lineage cells.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - altered neural glycosphingolipid profiles
    - altered receptor tyrosine kinase signaling
    evidence:
    - reference: PMID:37676252
      reference_title: Neural-specific alterations in glycosphingolipid biosynthesis and cell signaling associated with two human ganglioside GM3 synthase deficiency variants.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "To explore how loss of GM3 impacts neural-specific glycolipid glycosylation and cell signaling"
      explanation: Patient-derived neural lineage models directly investigate how GM3 loss alters neural glycolipid glycosylation and signaling.
- name: Glycosphingolipid remodeling
  description: >
    Loss of the GM3 branch alters glycosphingolipid composition and collateral
    glycan programs in patient cells and model systems.
  chemical_entities:
  - preferred_term: glycosphingolipid
    modifier: ABNORMAL
    term:
      id: CHEBI:24402
      label: glycosphingolipid
  biological_processes:
  - preferred_term: glycosphingolipid biosynthetic process
    modifier: ABNORMAL
    term:
      id: GO:0006688
      label: glycosphingolipid biosynthetic process
  evidence:
  - reference: PMID:24026681
    reference_title: "A mutation in a ganglioside biosynthetic enzyme, ST3GAL5, results in salt & pepper syndrome, a neurocutaneous disorder with altered glycolipid and glycoprotein glycosylation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "revealed collateral alterations in response"
    explanation: Patient fibroblast glycomic analysis supports broader glycosylation remodeling.
  - reference: PMID:37676252
    reference_title: Neural-specific alterations in glycosphingolipid biosynthesis and cell signaling associated with two human ganglioside GM3 synthase deficiency variants.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Altered GSL profiles in GM3SD cells"
    explanation: Patient-derived neural lineage cells show altered GSL profiles and downstream cellular changes.
  downstream:
  - target: Altered glycosphingolipid profile
    description: Loss of GM3-derived gangliosides produces a measurable abnormal glycosphingolipid profile in patient-derived cells.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37676252
      reference_title: Neural-specific alterations in glycosphingolipid biosynthesis and cell signaling associated with two human ganglioside GM3 synthase deficiency variants.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Altered GSL profiles in GM3SD cells"
      explanation: Patient-derived neural lineage cells show altered glycosphingolipid profiles downstream of GM3 synthase deficiency.
  - target: Neural cell signaling vulnerability
    description: Altered glycosphingolipid profiles perturb membrane and receptor signaling states.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37676252
      reference_title: Neural-specific alterations in glycosphingolipid biosynthesis and cell signaling associated with two human ganglioside GM3 synthase deficiency variants.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Altered GSL profiles in GM3SD cells"
      explanation: Altered glycosphingolipid profiles are directly observed in GM3 synthase-deficient neural lineage cells.
  - target: Abnormality of skin pigmentation
    description: >
      Glycolipid and glycoprotein glycosylation remodeling is associated with
      the neurocutaneous pigmentation phenotype.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:24026681
      reference_title: "A mutation in a ganglioside biosynthetic enzyme, ST3GAL5, results in salt & pepper syndrome, a neurocutaneous disorder with altered glycolipid and glycoprotein glycosylation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "altered dermal pigmentation"
      explanation: The salt-and-pepper syndrome report links ST3GAL5 disease to altered dermal pigmentation.
    - reference: ORPHA:370933
      reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "abnormalities of skin pigmentation"
      explanation: Orphanet records abnormal skin pigmentation as a feature.
  - target: Abnormal facial shape
    description: >
      Dysmorphic facial features are reported in ST3GAL5-related
      neurocutaneous disease, but the cached evidence does not resolve the
      intermediate morphogenetic mechanism.
    causal_link_type: UNKNOWN
    evidence:
    - reference: PMID:24026681
      reference_title: "A mutation in a ganglioside biosynthetic enzyme, ST3GAL5, results in salt & pepper syndrome, a neurocutaneous disorder with altered glycolipid and glycoprotein glycosylation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "dysmorphic facial features"
      explanation: The salt-and-pepper syndrome report lists dysmorphic facial features.
    - reference: ORPHA:370933
      reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Dysmorphic facial features may be associated."
      explanation: Orphanet records dysmorphic facial features as an associated finding.
- name: Neural cell signaling vulnerability
  description: >
    Complex ganglioside depletion in patient-derived neural lineage cells alters
    receptor tyrosine kinase abundance, O-GlcNAcylation, and apoptosis
    susceptibility, providing a plausible cellular route from glycosphingolipid
    biosynthesis failure to neurodevelopmental dysfunction.
  cell_types:
  - preferred_term: neural cell
    term:
      id: CL:0002319
      label: neural cell
  - preferred_term: migratory neural crest cell
    term:
      id: CL:0000333
      label: migratory neural crest cell
  biological_processes:
  - preferred_term: cell surface receptor protein tyrosine kinase signaling pathway
    modifier: ABNORMAL
    term:
      id: GO:0007169
      label: cell surface receptor protein tyrosine kinase signaling pathway
  - preferred_term: apoptotic process
    modifier: INCREASED
    term:
      id: GO:0006915
      label: apoptotic process
  evidence:
  - reference: PMID:37676252
    reference_title: Neural-specific alterations in glycosphingolipid biosynthesis and cell signaling associated with two human ganglioside GM3 synthase deficiency variants.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "exhibited increased apoptosis"
    explanation: Patient-derived neural crest cells show increased apoptosis and altered signaling.
  - reference: PMID:24026681
    reference_title: "A mutation in a ganglioside biosynthetic enzyme, ST3GAL5, results in salt & pepper syndrome, a neurocutaneous disorder with altered glycolipid and glycoprotein glycosylation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Morphant zebrafish embryos also exhibited increased apoptotic cell death"
    explanation: Zebrafish knockdown supports increased brain-region apoptosis after st3gal5 loss.
  - reference: PMID:18480157
    reference_title: Ganglioside depletion and EGF responses of human GM3 synthase-deficient fibroblasts.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "dampens membrane EGFR activation"
    explanation: Patient fibroblasts show altered EGFR signaling after ganglioside depletion.
  downstream:
  - target: Seizure
    description: Neural membrane and signaling disruption contributes to severe infantile epilepsy.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:15502825
      reference_title: Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Infantile-onset symptomatic epilepsy syndrome"
      explanation: The original clinical report defines the disease by infantile-onset symptomatic epilepsy.
    - reference: PMID:30209782
      reference_title: Oral Ganglioside Supplement Improves Growth and Development in Patients with Ganglioside GM3 Synthase Deficiency.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "intractable seizures"
      explanation: Clinical supplementation study lists intractable seizures as a core manifestation.
  - target: Global developmental delay
    description: Neural-lineage signaling and survival defects contribute to severe developmental impairment.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:370933
      reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "severe developmental delay or developmental regression"
      explanation: Orphanet records severe developmental delay as part of the progressive phenotype.
  - target: Visual impairment
    description: Neural tissue vulnerability contributes to cortical visual impairment and optic pathway disease.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:370933
      reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Visual impairment due to cortical atrophy"
      explanation: Orphanet links visual impairment to cortical atrophy.
  - target: Hearing impairment
    description: Ganglioside biology in neural tissues is linked to the sensorineural phenotype.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:34906476
      reference_title: GM3 synthase deficiency in non-Amish patients.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "optic atrophy or pale papillae, and hearing loss"
      explanation: The non-Amish cohort reports hearing loss among main features.
  - target: Irritability
    description: >
      Severe neural dysfunction in infancy is associated with prominent
      irritability.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30209782
      reference_title: Oral Ganglioside Supplement Improves Growth and Development in Patients with Ganglioside GM3 Synthase Deficiency.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "severe irritability, intractable seizures, and profound intellectual disability"
      explanation: Clinical supplementation study lists severe irritability alongside core neurologic features.
  - target: Feeding difficulties
    description: >
      Early neurologic disease is associated with poor feeding in infancy.
    causal_link_type: UNKNOWN
    evidence:
    - reference: ORPHA:370933
      reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "poor feeding, failure to thrive"
      explanation: Orphanet records poor feeding in the initial infantile presentation.
  - target: Failure to thrive
    description: >
      Infantile neurologic disease and poor feeding are associated with failure
      to thrive.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - poor feeding
    evidence:
    - reference: ORPHA:370933
      reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "poor feeding, failure to thrive"
      explanation: Orphanet lists poor feeding and failure to thrive together in the initial presentation.
  - target: Growth delay
    description: >
      Feeding difficulty, failure to thrive, and severe neurodevelopmental
      disease are associated with postnatal growth impairment.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - failure to thrive
    evidence:
    - reference: ORPHA:370933
      reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "followed by postnatal growth impairment"
      explanation: Orphanet records postnatal growth impairment in the later disease course.
  - target: Developmental regression
    description: >
      Neural-lineage signaling and survival defects are associated with
      developmental regression in the progressive disease course.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:370933
      reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "developmental delay or developmental regression"
      explanation: Orphanet explicitly includes developmental regression.
  - target: Intellectual disability
    description: >
      Severe neural dysfunction is associated with profound intellectual
      disability.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:34906476
      reference_title: GM3 synthase deficiency in non-Amish patients.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "severe to profound intellectual disability"
      explanation: The non-Amish cohort reports severe to profound intellectual disability.
  - target: Optic atrophy
    description: >
      Neural and optic pathway vulnerability is associated with optic atrophy or
      pale papillae.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:34906476
      reference_title: GM3 synthase deficiency in non-Amish patients.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "optic atrophy or pale papillae, and hearing loss"
      explanation: The non-Amish cohort reports optic atrophy or pale papillae.
  - target: Choreoathetosis
    description: >
      Neural signaling vulnerability is associated with hyperkinetic movement
      disorder including choreoathetosis.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:370933
      reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "choreoathetosis and hypotonic tetraparesis"
      explanation: Orphanet records choreoathetosis as a gradually appearing movement phenotype.
    - reference: PMID:34906476
      reference_title: GM3 synthase deficiency in non-Amish patients.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "14 of 16 had\na hyperkinetic movement disorder"
      explanation: The non-Amish cohort reports hyperkinetic movement disorder in 14 of 16 patients.
  - target: Hypotonia
    description: >
      Neural motor system involvement is associated with hypotonic tetraparesis.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:370933
      reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "hypotonic tetraparesis"
      explanation: Orphanet records hypotonic tetraparesis, supporting hypotonia.
  - target: Scoliosis
    description: >
      Scoliosis is reported in ST3GAL5-related salt-and-pepper syndrome, but the
      cached evidence does not resolve the intermediate skeletal or neuromotor
      mechanism.
    causal_link_type: UNKNOWN
    evidence:
    - reference: PMID:24026681
      reference_title: "A mutation in a ganglioside biosynthetic enzyme, ST3GAL5, results in salt & pepper syndrome, a neurocutaneous disorder with altered glycolipid and glycoprotein glycosylation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "severe intellectual disability, epilepsy, scoliosis, choreoathetosis, dysmorphic facial features and altered dermal pigmentation"
      explanation: The salt-and-pepper syndrome report includes scoliosis in the human clinical phenotype.
  - target: Microcephaly
    description: >
      Severe neurodevelopmental disease is associated with progressive
      microcephaly.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:35628171
      reference_title: Ganglioside GM3 Synthase Deficiency in Mouse Models and Human Patients.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "progressive microcephaly, intellectual"
      explanation: Review summarizes progressive microcephaly among human GM3 synthase deficiency features.
phenotypes:
- name: Irritability
  frequency: FREQUENT
  description: Irritability is an early clinical feature.
  phenotype_term:
    preferred_term: Irritability
    term:
      id: HP:0000737
      label: Irritability
  evidence:
  - reference: ORPHA:370933
    reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "initially characterized by irritability"
    explanation: Orphanet lists irritability among the initial features.
  - reference: PMID:30209782
    reference_title: Oral Ganglioside Supplement Improves Growth and Development in Patients with Ganglioside GM3 Synthase Deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "severe irritability, intractable seizures, and profound intellectual disability"
    explanation: The clinical supplementation study lists severe irritability as a manifestation.
- name: Failure to thrive
  frequency: FREQUENT
  description: Poor feeding and failure to thrive occur early in infancy.
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: ORPHA:370933
    reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "poor feeding, failure to thrive"
    explanation: Orphanet lists poor feeding and failure to thrive among initial features.
  - reference: PMID:30576498
    reference_title: Total loss of GM3 synthase activity by a normally processed enzyme in a novel variant and in all ST3GAL5 variants reported to cause a distinct congenital disorder of glycosylation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "failure to thrive, severe hearing, visual, motor, and cognitive impairment"
    explanation: A reported patient with a novel ST3GAL5 variant had failure to thrive.
- name: Feeding difficulties
  frequency: FREQUENT
  description: Poor feeding is an early infantile manifestation.
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: ORPHA:370933
    reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "poor feeding, failure to thrive"
    explanation: Orphanet lists poor feeding among initial features.
- name: Growth delay
  frequency: FREQUENT
  description: Postnatal growth impairment is part of the clinical course.
  phenotype_term:
    preferred_term: Growth delay
    term:
      id: HP:0001510
      label: Growth delay
  evidence:
  - reference: ORPHA:370933
    reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "postnatal growth impairment"
    explanation: Orphanet describes postnatal growth impairment.
  - reference: PMID:30209782
    reference_title: Oral Ganglioside Supplement Improves Growth and Development in Patients with Ganglioside GM3 Synthase Deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "growth and development were documented in these subjects"
    explanation: Growth improvement during supplementation supports growth delay as a clinical treatment target.
- name: Seizure
  frequency: FREQUENT
  description: Early-onset refractory or intractable seizures are a core manifestation.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: ORPHA:370933
    reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "early-onset refractory epilepsy"
    explanation: Orphanet lists early-onset refractory epilepsy.
  - reference: PMID:34906476
    reference_title: GM3 synthase deficiency in non-Amish patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "11 of 16 had epilepsy"
    explanation: The non-Amish cohort supports epilepsy as a frequent feature.
- name: Global developmental delay
  frequency: FREQUENT
  description: Severe global developmental impairment is typical and may include regression.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: ORPHA:370933
    reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "severe developmental delay or developmental regression"
    explanation: Orphanet describes severe developmental delay or regression.
  - reference: PMID:36833282
    reference_title: "Whole Exome Sequencing Reveals a Novel Homozygous Variant in the Ganglioside Biosynthetic Enzyme, ST3GAL5 Gene in a Saudi Family Causing Salt and Pepper Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "causing SPDRS with epilepsy, short stature, speech delay, and developmental\ndelay in all three affected members"
    explanation: The Saudi family report supports developmental delay in ST3GAL5-associated disease.
- name: Developmental regression
  frequency: FREQUENT
  description: Some affected individuals develop developmental regression after early delay.
  phenotype_term:
    preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
  evidence:
  - reference: ORPHA:370933
    reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "developmental delay or developmental regression"
    explanation: Orphanet explicitly includes developmental regression.
- name: Intellectual disability
  frequency: VERY_FREQUENT
  description: Severe to profound intellectual disability is a major manifestation.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: ORPHA:370933
    reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "profound intellectual disability"
    explanation: Orphanet lists profound intellectual disability.
  - reference: PMID:34906476
    reference_title: GM3 synthase deficiency in non-Amish patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "severe to profound intellectual disability"
    explanation: The non-Amish cohort found severe to profound intellectual disability in all reported patients.
- name: Hearing impairment
  frequency: FREQUENT
  description: Deafness or hearing loss occurs in the syndrome.
  phenotype_term:
    preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  evidence:
  - reference: ORPHA:370933
    reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "profound intellectual disability, deafness"
    explanation: Orphanet lists deafness as a feature.
  - reference: PMID:34906476
    reference_title: GM3 synthase deficiency in non-Amish patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "optic atrophy or pale papillae, and hearing loss"
    explanation: The non-Amish cohort identifies hearing loss among main features.
- name: Visual impairment
  frequency: FREQUENT
  description: Visual impairment can occur due to cortical atrophy, blindness, or optic atrophy.
  phenotype_term:
    preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  evidence:
  - reference: ORPHA:370933
    reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Visual impairment due to cortical atrophy"
    explanation: Orphanet lists visual impairment due to cortical atrophy.
  - reference: PMID:30576498
    reference_title: Total loss of GM3 synthase activity by a normally processed enzyme in a novel variant and in all ST3GAL5 variants reported to cause a distinct congenital disorder of glycosylation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "severe hearing, visual, motor, and cognitive impairment"
    explanation: A reported ST3GAL5-CDG patient had severe visual impairment.
- name: Optic atrophy
  frequency: FREQUENT
  description: Optic atrophy or pale papillae are reported in non-Amish patients.
  phenotype_term:
    preferred_term: Optic atrophy
    term:
      id: HP:0000648
      label: Optic atrophy
  evidence:
  - reference: PMID:34906476
    reference_title: GM3 synthase deficiency in non-Amish patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "optic atrophy or pale papillae, and hearing loss"
    explanation: The non-Amish cohort lists optic atrophy or pale papillae among main features.
- name: Choreoathetosis
  frequency: VERY_FREQUENT
  description: Hyperkinetic movement disorder commonly includes choreoathetosis.
  phenotype_term:
    preferred_term: Choreoathetosis
    term:
      id: HP:0001266
      label: Choreoathetosis
  evidence:
  - reference: ORPHA:370933
    reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "choreoathetosis and hypotonic tetraparesis"
    explanation: Orphanet lists choreoathetosis.
  - reference: PMID:34906476
    reference_title: GM3 synthase deficiency in non-Amish patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "14 of 16 had\na hyperkinetic movement disorder"
    explanation: >
      14 of 16 non-Amish patients had hyperkinetic movement disorder, placing
      choreoathetosis in the very frequent band.
- name: Hypotonia
  frequency: FREQUENT
  description: Hypotonia is included in the hypotonic tetraparesis described by Orphanet.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: ORPHA:370933
    reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "hypotonic tetraparesis"
    explanation: Orphanet's hypotonic tetraparesis description supports hypotonia.
- name: Abnormality of skin pigmentation
  frequency: FREQUENT
  description: Pigmentation abnormalities include freckle-like hyperpigmented and depigmented macules.
  phenotype_term:
    preferred_term: Abnormality of skin pigmentation
    term:
      id: HP:0001000
      label: Abnormality of skin pigmentation
  evidence:
  - reference: ORPHA:370933
    reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "abnormalities of skin pigmentation"
    explanation: Orphanet lists abnormal skin pigmentation.
  - reference: PMID:34906476
    reference_title: GM3 synthase deficiency in non-Amish patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "progressive skin pigmentation anomalies"
    explanation: The non-Amish cohort reports progressive skin pigmentation anomalies.
- name: Abnormal facial shape
  frequency: OCCASIONAL
  description: Dysmorphic facial features may be associated with the syndrome.
  phenotype_term:
    preferred_term: Abnormal facial shape
    term:
      id: HP:0001999
      label: Abnormal facial shape
  evidence:
  - reference: ORPHA:370933
    reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Dysmorphic facial features may be associated."
    explanation: Orphanet notes that dysmorphic facial features may be associated.
- name: Scoliosis
  frequency: OCCASIONAL
  description: Scoliosis has been reported in ST3GAL5-related salt-and-pepper syndrome.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:24026681
    reference_title: "A mutation in a ganglioside biosynthetic enzyme, ST3GAL5, results in salt & pepper syndrome, a neurocutaneous disorder with altered glycolipid and glycoprotein glycosylation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "severe intellectual disability, epilepsy, scoliosis, choreoathetosis, dysmorphic facial features and altered dermal pigmentation"
    explanation: The human salt-and-pepper syndrome report includes scoliosis.
  - reference: PMID:36833282
    reference_title: "Whole Exome Sequencing Reveals a Novel Homozygous Variant in the Ganglioside Biosynthetic Enzyme, ST3GAL5 Gene in a Saudi Family Causing Salt and Pepper Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "choreoathetosis, scoliosis, and dermal pigmentation along with dysmorphic facial"
    explanation: The Saudi family report summarizes scoliosis among SPDRS clinical features.
- name: Microcephaly
  frequency: FREQUENT
  description: Microcephaly is reported in a substantial fraction of non-Amish patients.
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  evidence:
  - reference: PMID:34906476
    reference_title: GM3 synthase deficiency in non-Amish patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "microcephaly"
    explanation: The non-Amish cohort supports microcephaly as a frequent feature.
  - reference: PMID:35628171
    reference_title: Ganglioside GM3 Synthase Deficiency in Mouse Models and Human Patients.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "progressive microcephaly, intellectual"
    explanation: The review summarizes progressive microcephaly among human patient features.
biochemical:
- name: Reduced GM3 synthase activity
  presence: DECREASED
  context: >
    Direct enzyme assays show loss of GM3 synthase activity from pathogenic
    ST3GAL5 variants.
  readouts:
  - target: ST3GAL5 GM3 synthase loss of function
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Reduced GM3 synthase activity reports the proximal ST3GAL5 enzymatic defect.
  evidence:
  - reference: PMID:30576498
    reference_title: Total loss of GM3 synthase activity by a normally processed enzyme in a novel variant and in all ST3GAL5 variants reported to cause a distinct congenital disorder of glycosylation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "revealed a complete loss of enzyme activity."
    explanation: Transfected-cell assays directly show complete loss of GM3 synthase activity for pathogenic variants.
- name: GM3 ganglioside depletion
  presence: ABSENT
  context: >
    Absent GM3 in plasma or cells is the direct chemical readout of the blocked
    ST3GAL5 sialyltransferase step.
  biomarker_term:
    preferred_term: ganglioside GM3
    term:
      id: CHEBI:84118
      label: ganglioside GM3
  readouts:
  - target: GM3 and downstream ganglioside depletion
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Absent GM3 ganglioside reports failure of the ST3GAL5-dependent biosynthetic step.
  evidence:
  - reference: PMID:15502825
    reference_title: Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "complete lack of GM3 ganglioside and its biosynthetic derivatives"
    explanation: Plasma glycosphingolipid analysis directly documents absent GM3 ganglioside.
- name: Complex ganglioside depletion
  presence: DECREASED
  context: >
    Downstream GM3-derived gangliosides are depleted because GM3 is the precursor
    for most complex gangliosides in neural tissue.
  biomarker_term:
    preferred_term: ganglioside
    term:
      id: CHEBI:28892
      label: ganglioside
  readouts:
  - target: GM3 and downstream ganglioside depletion
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Depletion of downstream gangliosides reports the broader biosynthetic consequence of absent GM3 synthase activity.
  evidence:
  - reference: PMID:30209782
    reference_title: Oral Ganglioside Supplement Improves Growth and Development in Patients with Ganglioside GM3 Synthase Deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "GM3 synthase deficiency (GM3D) causes an absence of GM3 and all downstream biosynthetic derivatives."
    explanation: This clinical study background supports absence of GM3 and downstream biosynthetic derivatives.
  - reference: PMID:37676252
    reference_title: Neural-specific alterations in glycosphingolipid biosynthesis and cell signaling associated with two human ganglioside GM3 synthase deficiency variants.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "GM3 and GM3-derived gangliosides were undetectable in cells carrying either variant"
    explanation: Patient-derived neural lineage cells independently show undetectable GM3-derived gangliosides.
- name: Altered glycosphingolipid profile
  presence: ABNORMAL
  context: >
    Patient-derived cells show broader glycosphingolipid remodeling beyond GM3
    and downstream ganglioside depletion.
  biomarker_term:
    preferred_term: glycosphingolipid
    term:
      id: CHEBI:24402
      label: glycosphingolipid
  readouts:
  - target: Glycosphingolipid remodeling
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: MONITORING
    interpretation: Altered GSL profiles report compensatory glycosphingolipid remodeling downstream of GM3 depletion.
  evidence:
  - reference: PMID:37676252
    reference_title: Neural-specific alterations in glycosphingolipid biosynthesis and cell signaling associated with two human ganglioside GM3 synthase deficiency variants.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Altered GSL profiles in GM3SD cells"
    explanation: Patient-derived neural lineage cells show altered glycosphingolipid profiles.
diagnosis:
- name: ST3GAL5 molecular genetic testing
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: MAXO:0000127
      label: genetic testing
  description: >
    Molecular testing for biallelic pathogenic ST3GAL5 variants confirms the
    diagnosis when the clinical and biochemical phenotype is compatible.
  results: Biallelic pathogenic ST3GAL5 variants support molecular diagnosis.
  evidence:
  - reference: PMID:34906476
    reference_title: GM3 synthase deficiency in non-Amish patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "clinical and molecular data from 16 non-Amish patients"
    explanation: The cohort used clinical and molecular data to define pathogenic ST3GAL5 disease.
  - reference: ORPHA:370933
    reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ST3GAL5 | ST3 beta-galactoside alpha-2,3-sialyltransferase 5"
    explanation: Orphanet identifies ST3GAL5 as the disease gene for molecular confirmation.
- name: Glycosphingolipid biochemical analysis
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  description: >
    Biochemical analysis of plasma or cellular glycosphingolipids can show lack
    of GM3 and downstream gangliosides with altered upstream glycosphingolipid
    species.
  results: Absence of GM3 and biosynthetic derivatives supports GM3 synthase deficiency.
  evidence:
  - reference: PMID:15502825
    reference_title: Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Biochemical analysis of plasma"
    explanation: Plasma glycosphingolipid analysis confirmed the biochemical defect in affected individuals.
  - reference: PMID:24026681
    reference_title: "A mutation in a ganglioside biosynthetic enzyme, ST3GAL5, results in salt & pepper syndrome, a neurocutaneous disorder with altered glycolipid and glycoprotein glycosylation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Glycolipid analysis confirmed a complete lack of GM3"
    explanation: Patient fibroblast glycolipid analysis confirmed absent GM3.
treatments:
- name: Oral ganglioside supplementation
  description: >
    Oral ganglioside-enriched dairy supplementation has been reported to produce
    transient improvements in growth and development in affected children, but
    benefits waned after about 12 months and durable restoration of endogenous
    ganglioside synthesis remains an unmet therapeutic goal.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
    therapeutic_agent:
    - preferred_term: ganglioside
      term:
        id: CHEBI:28892
        label: ganglioside
  target_phenotypes:
  - preferred_term: Growth delay
    term:
      id: HP:0001510
      label: Growth delay
  - preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  target_mechanisms:
  - target: GM3 and downstream ganglioside depletion
    treatment_effect: RESTORES
    description: Dietary gangliosides attempt to increase downstream ganglioside availability.
    evidence:
    - reference: PMID:39119456
      reference_title: Dietary gangliosides rescue GM3 synthase deficiency outcomes in mice accompanied by neurogenesis in the hippocampus.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "increased ganglioside levels and neurogenesis in the hippocampus"
      explanation: Mouse supplementation increased ganglioside levels and hippocampal neurogenesis.
  evidence:
  - reference: PMID:30209782
    reference_title: Oral Ganglioside Supplement Improves Growth and Development in Patients with Ganglioside GM3 Synthase Deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "received oral ganglioside supplement"
    explanation: The clinical study administered oral ganglioside-enriched dairy supplementation.
  - reference: PMID:30209782
    reference_title: Oral Ganglioside Supplement Improves Growth and Development in Patients with Ganglioside GM3 Synthase Deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "transient and gradually phased out"
    explanation: The study reports that clinical benefits appeared transient.
- name: Genetic counseling
  description: >
    Genetic counseling is appropriate for affected families because the disorder
    is autosomal recessive and molecular diagnosis clarifies recurrence risk.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: ORPHA:370933
    reference_title: "GM3 synthase deficiency (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal recessive"
    explanation: Autosomal recessive inheritance supports recurrence-risk counseling.
references:
- reference: ORPHA:370933
  title: GM3 synthase deficiency
  found_in:
  - GM3_Synthase_Deficiency-deep-research-fallback.md
- reference: PMID:15502825
  title: Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase.
  found_in:
  - GM3_Synthase_Deficiency-deep-research-fallback.md
- reference: PMID:18480157
  title: Ganglioside depletion and EGF responses of human GM3 synthase-deficient fibroblasts.
  found_in:
  - GM3_Synthase_Deficiency-deep-research-fallback.md
- reference: PMID:24026681
  title: "A mutation in a ganglioside biosynthetic enzyme, ST3GAL5, results in salt & pepper syndrome, a neurocutaneous disorder with altered glycolipid and glycoprotein glycosylation."
  found_in:
  - GM3_Synthase_Deficiency-deep-research-fallback.md
- reference: PMID:30209782
  title: Oral Ganglioside Supplement Improves Growth and Development in Patients with Ganglioside GM3 Synthase Deficiency.
  found_in:
  - GM3_Synthase_Deficiency-deep-research-fallback.md
- reference: PMID:30576498
  title: Total loss of GM3 synthase activity by a normally processed enzyme in a novel variant and in all ST3GAL5 variants reported to cause a distinct congenital disorder of glycosylation.
  found_in:
  - GM3_Synthase_Deficiency-deep-research-fallback.md
- reference: PMID:34906476
  title: GM3 synthase deficiency in non-Amish patients.
  found_in:
  - GM3_Synthase_Deficiency-deep-research-fallback.md
- reference: PMID:35628171
  title: Ganglioside GM3 Synthase Deficiency in Mouse Models and Human Patients.
  found_in:
  - GM3_Synthase_Deficiency-deep-research-fallback.md
- reference: PMID:36833282
  title: "Whole Exome Sequencing Reveals a Novel Homozygous Variant in the Ganglioside Biosynthetic Enzyme, ST3GAL5 Gene in a Saudi Family Causing Salt and Pepper Syndrome."
  found_in:
  - GM3_Synthase_Deficiency-deep-research-fallback.md
- reference: PMID:37676252
  title: Neural-specific alterations in glycosphingolipid biosynthesis and cell signaling associated with two human ganglioside GM3 synthase deficiency variants.
  found_in:
  - GM3_Synthase_Deficiency-deep-research-fallback.md
- reference: PMID:39119456
  title: Dietary gangliosides rescue GM3 synthase deficiency outcomes in mice accompanied by neurogenesis in the hippocampus.
  found_in:
  - GM3_Synthase_Deficiency-deep-research-fallback.md
📚

References & Deep Research

References

11
ORPHA:370933
GM3 synthase deficiency
No top-level findings curated for this source.
PMID:15502825
Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase.
No top-level findings curated for this source.
PMID:18480157
Ganglioside depletion and EGF responses of human GM3 synthase-deficient fibroblasts.
No top-level findings curated for this source.
PMID:24026681
A mutation in a ganglioside biosynthetic enzyme, ST3GAL5, results in salt & pepper syndrome, a neurocutaneous disorder with altered glycolipid and glycoprotein glycosylation.
No top-level findings curated for this source.
PMID:30209782
Oral Ganglioside Supplement Improves Growth and Development in Patients with Ganglioside GM3 Synthase Deficiency.
No top-level findings curated for this source.
PMID:30576498
Total loss of GM3 synthase activity by a normally processed enzyme in a novel variant and in all ST3GAL5 variants reported to cause a distinct congenital disorder of glycosylation.
No top-level findings curated for this source.
PMID:34906476
GM3 synthase deficiency in non-Amish patients.
No top-level findings curated for this source.
PMID:35628171
Ganglioside GM3 Synthase Deficiency in Mouse Models and Human Patients.
No top-level findings curated for this source.
PMID:36833282
Whole Exome Sequencing Reveals a Novel Homozygous Variant in the Ganglioside Biosynthetic Enzyme, ST3GAL5 Gene in a Saudi Family Causing Salt and Pepper Syndrome.
No top-level findings curated for this source.
PMID:37676252
Neural-specific alterations in glycosphingolipid biosynthesis and cell signaling associated with two human ganglioside GM3 synthase deficiency variants.
No top-level findings curated for this source.
PMID:39119456
Dietary gangliosides rescue GM3 synthase deficiency outcomes in mice accompanied by neurogenesis in the hippocampus.
No top-level findings curated for this source.

Deep Research

1
GM3 Synthase Deficiency Deep Research Fallback ▸

GM3 Synthase Deficiency Deep Research Fallback

Date: 2026-05-04T13:48Z

Provider Attempts

  • timeout 180 uv run deep-research-client research --template templates/disease_pathophysiology_research.md --var disease_name=GM3 synthase deficiency --var mondo_id=MONDO:0018274 --var category=Mendelian --provider falcon --output research/GM3_Synthase_Deficiency-deep-research-falcon.md --separate-citations research/GM3_Synthase_Deficiency-deep-research-falcon.md.citations.md
  • Result: timed out after the bounded 180-second run.
  • Completed artifact: none.
  • timeout 180 uv run deep-research-client research --template templates/disease_pathophysiology_research.md --var disease_name=GM3 synthase deficiency --var mondo_id=MONDO:0018274 --var category=Mendelian --provider openai --output research/GM3_Synthase_Deficiency-deep-research-openai.md --separate-citations research/GM3_Synthase_Deficiency-deep-research-openai.md.citations.md
  • Result: timed out after the bounded 180-second run.
  • Completed artifact: none.

No provider-generated deep-research narrative completed within the bounded runtime. Curation therefore proceeded from regenerated structured Orphanet evidence and sequentially fetched PubMed caches, without hand-editing any references_cache/*.md files.

Evidence Scope Used For Curation

Structured Source

  • ORPHA:370933 GM3 synthase deficiency structured record
  • Exact MONDO cross-reference: MONDO:0018274
  • Exact OMIM cross-reference: OMIM:609056
  • Synonym: ST3GAL5-CDG
  • Inheritance: autosomal recessive
  • Gene assertion: ST3GAL5, disease-causing germline loss of function
  • Definition supports impaired complex ganglioside synthesis with early irritability, poor feeding, failure to thrive, refractory epilepsy, later growth impairment, developmental delay or regression, profound intellectual disability, deafness, abnormal skin pigmentation, visual impairment, choreoathetosis, and hypotonic tetraparesis.

PubMed Records

  • PMID:15502825
  • Original Amish infantile-onset symptomatic epilepsy syndrome report.
  • Supports autosomal recessive disease, truncating SIAT9/ST3GAL5 variant, GM3 synthase's role in complex ganglioside biosynthesis, absent GM3 synthase activity, absent GM3 ganglioside and derivatives, and increased upstream glycosphingolipid species.
  • PMID:18480157
  • Patient fibroblast study.
  • Supports severe ganglioside depletion, lack of compensatory alternative ganglioside synthesis, reduced EGF-induced proliferation and migration, reduced EGFR binding, and dampened EGFR activation.
  • PMID:24026681
  • Salt and pepper syndrome ST3GAL5 paper.
  • Supports severe intellectual disability, epilepsy, choreoathetosis, dysmorphic and pigmentation features, ST3GAL5 p.E332K, complete GM3 lack in patient fibroblasts, collateral glycolipid and glycoprotein glycosylation changes, and increased apoptosis in zebrafish brain regions after st3gal5 knockdown.
  • PMID:30209782
  • Human oral ganglioside supplementation study.
  • Supports absence of GM3 and downstream derivatives, severe irritability, intractable seizures, profound intellectual disability, oral ganglioside enriched dairy supplementation, improved growth and development, transient benefit, and need for endogenous ganglioside restoration strategies.
  • PMID:30576498
  • Variant enzyme-assay paper.
  • Supports ST3GAL5-CDG as a GM3 synthase disorder, failure to thrive and severe hearing, visual, motor, and cognitive impairment in a reported patient, and complete loss of enzyme activity across pathogenic variants.
  • PMID:34906476
  • Non-Amish patient cohort.
  • Supports biallelic ST3GAL5 loss of function, 16 affected non-Amish patients, severe to profound intellectual disability in all patients, hyperkinetic movement disorder in 14 of 16, epilepsy in 11 of 16, microcephaly in 9 of 16, progressive skin pigmentation anomalies, optic atrophy or pale papillae, and hearing loss.
  • PMID:35628171
  • Review of human disease and mouse models.
  • Supports ST3GAL5/GM3 synthase conversion of lactosylceramide to GM3, neural ganglioside biology, human progressive microcephaly, intellectual disability, dyskinetic movements, blindness, deafness, intractable seizures, pigment changes, and mouse-model limitations.
  • PMID:36833282
  • Saudi family report.
  • Supports ST3GAL5-associated salt and pepper developmental regression syndrome with epilepsy, profound intellectual disability, choreoathetosis, scoliosis, pigmentation, dysmorphism, novel homozygous ST3GAL5 variant, speech delay, and developmental delay.
  • PMID:37676252
  • Patient-derived iPSC/neural crest cell study.
  • Supports undetectable GM3 and GM3-derived gangliosides, elevated LacCer precursor, altered cell-surface proteome, O-GlcNAcylation, receptor tyrosine kinase abundance, increased apoptosis, and EGFR-inhibitor sensitivity in GM3SD neural lineage cells.
  • PMID:39119456
  • Dietary ganglioside supplementation mouse study.
  • Supports absence of GM3 and downstream derivatives, clinical features in affected individuals, prior human supplementation improvements, improved cognitive function in supplemented GM3 synthase-deficient mice, and increased ganglioside levels plus hippocampal neurogenesis.

Integration Notes

The YAML models GM3 synthase deficiency as a ST3GAL5 loss-of-function glycosphingolipid biosynthesis disorder. ST3GAL5 encodes lactosylceramide alpha-2,3-sialyltransferase activity, which produces ganglioside GM3 from lactosylceramide. Loss of that enzyme depletes GM3 and downstream ganglioside derivatives, alters broader glycosphingolipid and glycoprotein glycosylation, and perturbs membrane and receptor signaling in patient-derived neural lineage cells. The curated phenotype model emphasizes the severe infantile neurologic, growth, sensory, movement, and pigmentation phenotype supported by Orphanet and clinical cohorts.

Treatment evidence remains limited. The only disease-directed human treatment evidence found in the bounded literature scope was oral ganglioside-enriched dairy supplementation, which reported early growth and developmental improvements that appeared transient. The YAML therefore avoids a broad supportive-care treatment claim unless a direct management reference is added, and records autosomal recessive genetic counseling separately.